GLP-1 Peptide Atlas, by Delfa

CompletedPhase 1

A Study of Orforglipron (LY3502970) to Compare a Single Capsule and Multiple Capsules in Healthy Participants

A Phase 1, Open-Label, Multiple-Dose Study to Investigate the Comparability of the Pharmacokinetics of Orforglipron (LY3502970) Single Capsule and Multiple Capsules in Healthy Participants

Lead sponsor

Eli Lilly and Company

Asset

Orforglipron

Oral · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Healthy volunteers

Key I/E criterion

•BMI 23-35

Primary endpoints

•Steady-state AUC of Orforglipron (Fasted State)•PK: Steady-state Maximum Concentration (Cmax) of Orforglipron (Fasted State)•PK: Steady-state AUC of Orforglipron (Fed State)

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06692348

Org study ID27228

Secondary IDJ2A-JE-GZPMEli Lilly and Company

Timeline

Milestones

Study first posted2024-11-18actual

Study start2024-12-13actual

Primary completion2025-06-09actual

Study completion2025-06-09actual

Last update posted2025-06-24actual

Assets

Investigational agents

Orforglipron

Study populations

Who this study enrolls

Healthy volunteers

Eligibility

Who can enroll

Minimum age18 Years

Maximum age65 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•Have a stable body weight, that is, less than a 5% body weight change, for 1 month prior to randomization and body mass index (BMI) within the range 23.0 to 35.0 kilogram per square meter (kg/m²), inclusive

•Have safety laboratory test results within normal reference range for the population or investigative site, or results with acceptable deviations that are judged to be not clinically significant by the investigator

•Have venous access sufficient to allow for blood sampling

•Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures

Exclusion criteria

•Have a hemoglobin A1c (HbA1c) test level greater than or equal to 6.5%

•Have an estimated glomerular filtration rate less than 30 milliliter per minute per 1.73 square meter (mL/min/1.73m²)

•Have a history of significant active or unstable major depressive disorder or other severe psychiatric disorder, for example, schizophrenia, bipolar disorder, or other serious mood or anxiety disorder within the 2 years prior to screening

•Actively suicidal and therefore deemed to be at significant risk for suicide

•Have a known clinically significant gastric emptying abnormality

•Have history or presence of acute or chronic pancreatitis or an elevation in serum lipase or amylase levels greater than 3 times the upper limit of normal (ULN)

•Have an abnormal blood pressure (BP), pulse rate, or both

•Have difficulty swallowing capsules

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Safety / tolerability / PK

4 endpoints

Primary/protocol endpoint

Pharmacokinetics (PK): Steady-state Area Under the Concentration Versus Time Curve (AUC) of Orforglipron (Fasted State)

Time frame:Week 3 Through Week 16

AUC₀–∞

concentration, descriptive

Primary/protocol endpoint

PK: Steady-state Maximum Concentration (Cmax) of Orforglipron (Fasted State)

Time frame:Week 3 Through Week 16

Cmax

concentration, descriptive

Primary/protocol endpoint

PK: Steady-state AUC of Orforglipron (Fed State)

Time frame:Week 3 Through Week 16

AUC₀–∞

concentration, descriptive

Primary/protocol endpoint

PK: Steady-state Cmax of Orforglipron (Fed State)

Time frame:Week 3 Through Week 16

Cmax

concentration, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.